Sells MRI-guided ultrasound systems and single-use devices for prostate and other tissue ablation to physicians.
10-K for FY2025, filed Mar 5, 2026We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free…View ↗
Our business model consists of two components - sales of capital equipment and recurring non-capital equipment which includes one-time-use…View ↗
The physician is in charge of using the Profound devices and decides which tissue needs to be ablated to impart therapeutic effect. We…View ↗
Recurring non-capital sales make up 60% of revenue: customers buy one-time-use devices, generally counted at shipment, while extended-warranty services are spread over the coverage period. Capital equipment makes up 40%; systems, installation and training are generally counted at shipment.
10-K for FY2025, filed Mar 5, 2026
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$16.1M
10-K for FY2025, filed Mar 5, 2026
$16.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Recurring - non-capital
|
60% |
Recurring - non-capital, FY2025
$9.7M Sources
|
|
|
Capital equipment
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
40% |
Capital equipment, FY2025
$6.4M Sources
|
Sold outright |
Hospitals and treatment sites can buy TULSA-PRO directly or through distributors; customers purchasing systems through Cook obtain single-use disposables and service contracts directly from Profound.
10-K for FY2025, filed Mar 5, 2026 8-K, filed Nov 3, 2026Capital equipment revenue consists of the sale of capital equipment including installation and training amounts, which includes sales to…View ↗
The agreement establishes an additional new capital equipment sales channel for Profound by bringing its TULSA-PRO system into the…View ↗
Under the agreement, Cook will purchase TULSA-PRO systems from Profound at a predetermined transfer price for distribution in the United…View ↗
Profound’s existing capital sales team will continue to sell TULSA-PRO directly to sites with compatible MRI systems. Together, these…View ↗
No. It lost $42.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$7.7MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Nov 12, 2026
On November 5, 2026, the Board approved a leadership transition plan pursuant to which, effective January 15, 2027 (the “Transition Date”)…View ↗
8-K, filed Nov 3, 2026
Under the Agreement, Profound U.S. appointed Cook as a non-exclusive distributor of the Company’s TULSA-PRO® system (the “Products”) in the…View ↗
Growing. Revenue grew 2.3x in 4 years, from $6.9M in FY2021 to $16.1M in FY2025, about 24% a year.
Loading...